Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06603220 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
A Phase 2 study, sponsored by Evommune.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT06603220: Completed Phase 2 study, sponsored by Evommune.
NCT06603220 is a Phase 2 study that has completed, run by Evommune. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06603220, a Phase 2 study, has completed, sponsored by Evommune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.
Primary Outcome
Safety will be assessed by the total number of subjects with at least one TEAE
Interventions
- DRUG Oral EVO756 300 mg QD
- DRUG Oral EVO756 50 mg BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-08-14 |
| Est. Completion | 2025-05-08 |
| Phase | Phase 2 |
What the finished NCT06603220 record still lists
NCT06603220 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Oral EVO756 300 mg QD is the first listed.
NCT06603220 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06603220 about?
NCT06603220 is a clinical study titled "A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria". This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.
What is the current status of trial NCT06603220?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-08-14. Estimated completion is 2025-05-08.
What interventions are being tested in trial NCT06603220?
The interventions under investigation include: Oral EVO756 300 mg QD (DRUG), Oral EVO756 50 mg BID (DRUG).
Who is sponsoring clinical trial NCT06603220?
This trial is sponsored by Evommune, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06603220's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI